

FDA adds Fasenra indication for severe asthma in children

April 17 2024, by Lori Solomon



The U.S. Food and Drug Administration has approved an additional indication for AstraZeneca's Fasenra (benralizumab) as an add-on maintenance treatment for patients aged 6 to 11 years with severe asthma and an eosinophilic phenotype.

This indication was supported by evidence from the Phase III TATE trial, as well as [data](#) from additional well-controlled trials in adult and adolescent populations. Results among [children](#) aged 6 to 11 years old show that Fasenra met the primary end points, demonstrating pharmacokinetics and pharmacodynamics with severe eosinophilic asthma. The [safety](#) and tolerability results were also consistent with the known profile.

The recommended dose for Fasenra is 30 mg for patients ages 6 years and older who weigh ≥ 35 kg, while a new 10-mg dose will be available for patients aged 6 to 11 years who weigh

Citation: FDA adds Fasenra indication for severe asthma in children (2024, April 17) retrieved 16 May 2024 from <https://medicalxpress.com/news/2024-04-fda-fasenra-indication-severe-asthma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.